PMID- 27065776
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160412
LR  - 20201001
IS  - 1611-2156 (Print)
IS  - 1611-2156 (Electronic)
IS  - 1611-2156 (Linking)
VI  - 15
DP  - 2016
TI  - Clinical effects of topical antifungal therapy in chronic rhinosinusitis: a 
      randomized, double-blind, placebo-controlled trial of intranasal fluconazole.
PG  - 95-102
LID - 10.17179/excli2015-678 [doi]
AB  - Several studies have been in favor of fungi as a possible pathogenesis of chronic 
      rhinosinusitis (CRS); however, to date, there is no scientific consensus about 
      the use of antifungal agents in disease management. The aim of the present study 
      was to investigate the efficacy of intranasal fluconazole in improving disease 
      symptoms and objective outcomes of patients with CRS. A randomized, double-blind, 
      placebo-controlled study was conducted on 54 patients who were diagnosed with CRS 
      and had not been responsive to routine medical treatments. They were randomly 
      assigned to receive either fluconazole nasal drop 0.2 % or placebo in addition to 
      the standard regimen for a duration of 8 weeks. Patients' outcomes were evaluated 
      according to Sino-Nasal Outcome Test 20 (SNOT-20), endoscopic scores, and 
      Computed Tomography (CT) scores. No statistically significant difference was 
      found in SNOT-20 (p = 0.201), endoscopic (p = 0.283), and CT scores (p = 0.212) 
      of the patients at baseline and after 8-week course of treatment between drug and 
      placebo group. Similar to many studies, the use of topical antifungal treatment 
      for patients with CRS was not shown to be significantly effective. However, 
      further studies are needed to obtain high levels of consistent evidence in order 
      to arrive at a decision whether antifungal therapy is effective in management of 
      CRS or not.
FAU - Hashemian, Farshad
AU  - Hashemian F
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Islamic Azad University, 
      Pharmaceutical Sciences Branch, Tehran, Iran.
FAU - Hashemian, Farnaz
AU  - Hashemian F
AD  - Department of Otolaryngology, Hamadan University of Medical Sciences, Hamadan, 
      Iran.
FAU - Molaali, Najmeh
AU  - Molaali N
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Islamic Azad University, 
      Pharmaceutical Sciences Branch, Tehran, Iran.
FAU - Rouini, Mohammadreza
AU  - Rouini M
AD  - Department of Pharmaceutics, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Roohi, Elnaz
AU  - Roohi E
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Islamic Azad University, 
      Pharmaceutical Sciences Branch, Tehran, Iran.
FAU - Torabian, Saadat
AU  - Torabian S
AD  - Department of Community Medicine, School of Medicine, Hamadan University of 
      Medical Sciences, Hamadan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20160205
PL  - Germany
TA  - EXCLI J
JT  - EXCLI journal
JID - 101299402
PMC - PMC4822190
OTO - NOTNLM
OT  - antifungal therapy
OT  - chronic rhinosinusitis
OT  - clinical trial
OT  - fluconazole
EDAT- 2016/04/12 06:00
MHDA- 2016/04/12 06:01
PMCR- 2016/02/05
CRDT- 2016/04/12 06:00
PHST- 2015/11/13 00:00 [received]
PHST- 2016/01/26 00:00 [accepted]
PHST- 2016/04/12 06:00 [entrez]
PHST- 2016/04/12 06:00 [pubmed]
PHST- 2016/04/12 06:01 [medline]
PHST- 2016/02/05 00:00 [pmc-release]
AID - 2015-678 [pii]
AID - Doc95 [pii]
AID - 10.17179/excli2015-678 [doi]
PST - epublish
SO  - EXCLI J. 2016 Feb 5;15:95-102. doi: 10.17179/excli2015-678. eCollection 2016.